Valley Forge Investment Consultants’s NervGen Pharma NGEN Stock Holding History

Valley Forge Investment Consultants’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$293K	Buy	+77,698	New	+$337K	0.09%	66

Other funds holding NGEN

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Valley Forge Investment Consultants's NGEN Position: Q1 2026 in Review

Valley Forge Investment Consultants opened a new position in NervGen Pharma (NGEN) in Q1 2026: 77,698 shares worth $293K. The stake represents 0.09% of the portfolio and ranks #66 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

Valley Forge Investment Consultants held 77,698 shares of NervGen Pharma worth $293K as of Q1 2026.
NervGen Pharma was a new Valley Forge Investment Consultants position in Q1 2026.
NervGen Pharma made up 0.09% of Valley Forge Investment Consultants's portfolio in Q1 2026, its #66 holding.
45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on Valley Forge Investment Consultants's 13F filing for Q1 2026, filed 21 Apr 2026.